UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 13,865 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 2.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 690,191 shares of the company's stock after acquiring an additional 13,865 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.81% of CRISPR Therapeutics worth $27,166,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Intellectus Partners LLC lifted its holdings in shares of CRISPR Therapeutics by 3.6% during the 4th quarter. Intellectus Partners LLC now owns 7,131 shares of the company's stock worth $281,000 after acquiring an additional 250 shares during the period. Farrow Financial Inc. lifted its holdings in shares of CRISPR Therapeutics by 1.4% during the 4th quarter. Farrow Financial Inc. now owns 20,097 shares of the company's stock worth $777,000 after acquiring an additional 270 shares during the period. Kestra Private Wealth Services LLC lifted its holdings in shares of CRISPR Therapeutics by 1.5% during the 4th quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company's stock worth $812,000 after acquiring an additional 310 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of CRISPR Therapeutics by 7.6% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company's stock worth $215,000 after acquiring an additional 372 shares during the period. Finally, Horizon Kinetics Asset Management LLC lifted its holdings in shares of CRISPR Therapeutics by 4.3% during the 4th quarter. Horizon Kinetics Asset Management LLC now owns 10,682 shares of the company's stock worth $420,000 after acquiring an additional 443 shares during the period. 69.20% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on CRSP shares. TD Cowen upgraded shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 target price for the company in a research report on Wednesday, February 12th. Cantor Fitzgerald reiterated a "neutral" rating on shares of CRISPR Therapeutics in a research report on Wednesday, February 19th. Chardan Capital dropped their target price on shares of CRISPR Therapeutics from $84.00 to $82.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. JMP Securities reiterated a "market outperform" rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday, May 21st. Finally, Truist Financial increased their target price on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a "buy" rating in a research report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, CRISPR Therapeutics presently has a consensus rating of "Hold" and an average price target of $71.75.

CRISPR Therapeutics Trading Down 2.0%

Shares of NASDAQ:CRSP traded down $0.74 during trading on Friday, hitting $36.04. 2,078,440 shares of the company's stock were exchanged, compared to its average volume of 1,709,615. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $67.88. The firm has a 50-day moving average price of $36.59 and a two-hundred day moving average price of $41.43. The firm has a market cap of $3.11 billion, a P/E ratio of -8.25 and a beta of 1.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same quarter last year, the firm posted ($1.43) EPS. The business's revenue was up 71.6% compared to the same quarter last year. As a group, research analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 9,973 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $423,054.66. Following the completion of the transaction, the chief executive officer now owns 180,890 shares in the company, valued at approximately $7,673,353.80. The trade was a 5.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Naimish Patel sold 3,932 shares of the business's stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total transaction of $141,316.08. Following the transaction, the insider now owns 6,068 shares of the company's stock, valued at approximately $218,083.92. This represents a 39.32% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 17,953 shares of company stock worth $736,087. 4.10% of the stock is currently owned by company insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.